TY - JOUR
T1 - The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata
AU - Gelhorn, Heather L.
AU - Cutts, Katelyn
AU - Edson-Heredia, Emily
AU - Wright, Peter
AU - Delozier, Amy
AU - Shapiro, Jerry
AU - Senna, Maryanne
AU - Tosti, Antonella
N1 - Funding Information:
The authors would like to thank the research participants for participating in the study. This research study was funded by Eli Lilly and Company. Eli Lilly and Company will be funding the journal?s Rapid Service Fees. Dawn Ri?chard of Evidera provided editorial assisting for the manuscript, which was funded by Eli Lilly and Company. The authors received no financial support for the research, authorship, and/or publication of this article. The authors have given their approval for this version to be published. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors provided critical feedback and helped shape the research, analysis and manuscript. Amy DeLozier, Peter Wright and Emily Edson-Heredia are employees and shareholders of Eli Lilly and Company. Katelyn Cutts and Heather Gelhorn are employees of Evidera, a research organization who conducted the study under contract by Eli Lilly and Company. Maryanne Senna has served on advisory boards and/or have been a consultant for Arena Pharmaceuticals, Concert Pharmaceuticals Inc., Eli Lilly and Company, Pfizer Inc, and Follica, Inc. She is a clinical trial investigator for Concert Pharmaceuticals Inc., Eli Lilly and Company and Follica, Inc. Jerry Shapiro is a consultant or clinical trial investigator for Pfizer Inc. and a consultant for Eli Lilly and Company. Antonella Tosti is a consultant for DS Laboratories, Monat Global, Almirall, Tirthy Madison, Leo Pharmaceuticals, Bristol Myers Squibb and P&G; and is is a compensated consultant/advisory board member for Eli Lilly and Company, sponsor of the study. The study was approved by an institutional review board (IRB) Ethical & Independent Review Services (E&I study number: 20154-01; 15 September 2020) prior to the initiation of any participant recruitment. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Funding Information:
This research study was funded by Eli Lilly and Company. Eli Lilly and Company will be funding the journal’s Rapid Service Fees.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - Introduction: Alopecia areata (AA) is an autoimmune disease characterized by hair loss. Patients with AA experience a range of social and emotional impacts, and the lack of effective treatments and multiple affected locations can deepen the burden of illness. The objective of the current study was to assess health-related quality of life (HRQL) among patients with AA, and to evaluate the relationship between patient-reported AA severity, HRQL and treatment patterns. Methods: A web survey was completed by participants recruited through the National Alopecia Areata Foundation. The survey included questions on disease characteristics, burden and impact (evaluated by the Skindex-16 for AA and items on work/school and sexual relationships), healthcare utilization and treatment experience. Analyses were conducted for the overall sample and by key subgroups, including AA severity and disease duration. Results: A total of 1327 participants with AA completed the survey. The mean age was 39.7 [standard deviation (SD) 12.3] years and 58.4% were female. On average, participants had experienced signs and symptoms of AA for 11.5 years (SD 12.5) and were diagnosed by a healthcare provider (HCP) 10.5 (SD 12.2) years ago. Participants reported a range of severity of current scalp hair loss, including 0% (2.6%), 1–20% (39.8%), 21–49% (26.2%), 50–94% (10.2%) and 95–100% (21.3%). Participants reporting 95–100% of scalp hair missing were less likely to be currently seeing an HCP and to currently be on treatments for AA. There was a non-linear relationship between HRQL and current AA severity. Participants with 1–20% to 50–94% of current scalp hair missing reported higher symptom, functioning and emotional impacts due to AA than participants with 0% missing scalp hair and/or 95–100% missing scalp hair. Similar findings were observed for current eyebrow and eyelash severity, except for emotional impacts. Conclusion: Severity of AA plays an important role in understanding the burden of illness and healthcare patterns of people living with AA.
AB - Introduction: Alopecia areata (AA) is an autoimmune disease characterized by hair loss. Patients with AA experience a range of social and emotional impacts, and the lack of effective treatments and multiple affected locations can deepen the burden of illness. The objective of the current study was to assess health-related quality of life (HRQL) among patients with AA, and to evaluate the relationship between patient-reported AA severity, HRQL and treatment patterns. Methods: A web survey was completed by participants recruited through the National Alopecia Areata Foundation. The survey included questions on disease characteristics, burden and impact (evaluated by the Skindex-16 for AA and items on work/school and sexual relationships), healthcare utilization and treatment experience. Analyses were conducted for the overall sample and by key subgroups, including AA severity and disease duration. Results: A total of 1327 participants with AA completed the survey. The mean age was 39.7 [standard deviation (SD) 12.3] years and 58.4% were female. On average, participants had experienced signs and symptoms of AA for 11.5 years (SD 12.5) and were diagnosed by a healthcare provider (HCP) 10.5 (SD 12.2) years ago. Participants reported a range of severity of current scalp hair loss, including 0% (2.6%), 1–20% (39.8%), 21–49% (26.2%), 50–94% (10.2%) and 95–100% (21.3%). Participants reporting 95–100% of scalp hair missing were less likely to be currently seeing an HCP and to currently be on treatments for AA. There was a non-linear relationship between HRQL and current AA severity. Participants with 1–20% to 50–94% of current scalp hair missing reported higher symptom, functioning and emotional impacts due to AA than participants with 0% missing scalp hair and/or 95–100% missing scalp hair. Similar findings were observed for current eyebrow and eyelash severity, except for emotional impacts. Conclusion: Severity of AA plays an important role in understanding the burden of illness and healthcare patterns of people living with AA.
KW - Alopecia areata
KW - Health-related quality of life
KW - Healthcare
KW - Survey
KW - Symptom severity
KW - Treatment patterns
UR - http://www.scopus.com/inward/record.url?scp=85127318438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127318438&partnerID=8YFLogxK
U2 - 10.1007/s13555-022-00702-4
DO - 10.1007/s13555-022-00702-4
M3 - Article
AN - SCOPUS:85127318438
VL - 12
SP - 989
EP - 997
JO - Dermatology and Therapy
JF - Dermatology and Therapy
SN - 2190-9172
IS - 4
ER -